A NEW ERA...

The accelerating rate of chronic disease has become a global health crisis.

As millions of people move from early to advanced stages of chronic diseases, the cost of treatment becomes unsustainable.

In the last few decades beneficial bacteria have been prescribed for gastrointestinal health.

The new era of beneficial bacteria is focused on the production of new medicines from the bacterial metabolites.


Our showcase medicines

Statin

Medlab has developed multiple patented medicines and delivery systems, including:

  • Bacteria which have direct efficacy when they are delivered to the right region of the gut.
  • Bacteria that produce compounds with specific medicinal properties including a metabolite that improves lean muscle mass and prevents age-related muscle wasting.
  • Bacteria to improve glucose management
  • and reduce cardiovascular risk factors.
  • Bacterial and their metabolites to treat chronic kidney disease.
  • A natural compound (orotate) combined with bacteria to provide a ground breaking medical therapeutic for treatment-resistant depression.
  • Nutraceutical and Pharmaceutical products delivered by nanotechnology to improve bioavailability and efficacy. The technology delivers the active compound as a buccal or nasal spray, providing fast and effective absorption with higher bioavailability.
  • NanoCelle application to Atorastatin Liptor - cholesterol lowering pharmaceutical
  • NanoCelle application to Insulin - for type II diabetic patients